GSK to Divest Over-The-Counter Brands for £426 Million

GlaxoSmithKline yesterday announced that they are to divest a number of non-core over-the-counter (OTC) brands in the USA, Canada and Europe to Prestige Brands Holdings for £426 million. The intention to divest the brands had been announced in February 2011, and was proposed to realise value for shareholders, and to simplify GlaxoSmithKline’s consumer healthcare business. 

Continue Reading